PROCYTOX TAB 50MG TABLET Canada - English - Health Canada

procytox tab 50mg tablet

baxter corporation - cyclophosphamide - tablet - 50mg - cyclophosphamide 50mg - antineoplastic agents

PROCYTOX POWDER FOR SOLUTION Canada - English - Health Canada

procytox powder for solution

baxter corporation - cyclophosphamide - powder for solution - 200mg - cyclophosphamide 200mg - antineoplastic agents

PROCYTOX POWDER FOR SOLUTION Canada - English - Health Canada

procytox powder for solution

baxter corporation - cyclophosphamide - powder for solution - 500mg - cyclophosphamide 500mg - antineoplastic agents

PROCYTOX POWDER FOR SOLUTION Canada - English - Health Canada

procytox powder for solution

baxter corporation - cyclophosphamide - powder for solution - 1000mg - cyclophosphamide 1000mg - antineoplastic agents

PROCYTOX POWDER FOR SOLUTION Canada - English - Health Canada

procytox powder for solution

baxter corporation - cyclophosphamide - powder for solution - 2000mg - cyclophosphamide 2000mg - antineoplastic agents

BLENOXANE PWS 15UNIT POWDER FOR SOLUTION Canada - English - Health Canada

blenoxane pws 15unit powder for solution

bristol labs division of bristol-myers squibb - bleomycin sulfate - powder for solution - 15unit - bleomycin sulfate 15unit - antineoplastic agents

VERAPAMIL HYDROCHLORIDE PM capsule extended release United States - English - NLM (National Library of Medicine)

verapamil hydrochloride pm capsule extended release

avera mckennan hospital - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 100 mg

VERAPAMIL HYDROCHLORIDE PM- verapamil hydrochloride capsule, extended release United States - English - NLM (National Library of Medicine)

verapamil hydrochloride pm- verapamil hydrochloride capsule, extended release

mylan pharmaceuticals inc. - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 100 mg - verapamil hydrochloride extended-release capsules (pm) for oral use are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a va

VERELAN PM verapamil hydrochloride capsule extended release United States - English - NLM (National Library of Medicine)

verelan pm verapamil hydrochloride capsule extended release

bryant ranch prepack - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 300 mg

VERAPAMIL HYDROCHLORIDE capsule, extended release United States - English - NLM (National Library of Medicine)

verapamil hydrochloride capsule, extended release

physicians total care, inc. - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 100 mg - verapamil hydrochloride extended-release capsules (pm) for oral use are indicated for the management of essential hypertension. verapamil is contraindicated in: - severe left ventricular dysfunction [see warnings and precautions (5.1)] . - hypotension (less than 90 mm hg systolic pressure) or cardiogenic shock. - sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). - second- or third-degree av block (except in patients with a functioning artificial ventricular pacemaker). - patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g.,  wolff-parkinson-white, lown-ganong-levine syndromes) [see warnings and precautions (5.4)]. reproduction studies have been performed in rabbits and rats at oral doses up to 1.9 (15 mg/kg/day) and 7.5 (60 mg/kg/day) times the human oral daily dose, respectively, and have revealed no evidence of teratogenicity. in the rat, however, this multiple of the human dose was embryocidal and retarded fetal growth and devel